References of N-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-
yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-
oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]
amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-
oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-
imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
Title: Goserelin
CAS Registry Number: 65807-02-5
CAS Name: 6-[
O-(1,1-Dimethylethyl)-D-serine]-10-deglycinamideluteinizing hormone-releasing factor (pig) 2-(aminocarbonyl)hydrazide
Synonyms: D-Ser(But)6Azgly10-gonadorelin; D-Ser(But)6Azgly10-luliberin
Manufacturers' Codes: ICI-118630
Molecular Formula: C59H84N18O14
Molecular Weight: 1269.41
Percent Composition: C 55.82%, H 6.67%, N 19.86%, O 17.65%
Literature References: Synthetic peptide agonist analog of LH-RH,
q.v. Prepn: A. S. Dutta
et al., DE 2720245;
eidem, US 4100274 (1977, 1978 both to I.C.I.);
eidem, J. Med. Chem. 21, 1018 (1978). Radioimmunoassay in serum: R. N. Clayton
et al., Clin. Endocrinol. 22, 453 (1985). Endocrine effects in women: C. P. West, D. T. Baird,
ibid. 26, 213 (1987). Review of pharmacokinetics and therapeutic efficacy in sex hormone related disorders: P. Chrisp, K. L. Goa,
Drugs 41, 254-288 (1991). Clinical trial in treatment of uterine fibroids: J. Gerris
et al., Horm. Res. 45, 279 (1996); in prostate cancer: M. Bolla
et al., N. Engl. J. Med. 337, 295 (1997).
Derivative Type: Acetate
Trademarks: Zoladex (AstraZeneca)
Literature References: C59H84N18O14.xC2H4O2, where x = 1 to 2.4.
Properties: Off-white powder. Freely sol in acetic acid; sol in water, 0.1M HCl, 0.1M NaCl, DMF, DMSO. Insol in acetone, chloroform, ether.
Therap-Cat: Antineoplastic (hormonal).
Keywords: Antineoplastic (Hormonal); LH-RH Analogs; LH-RH Agonist.